sign free newsletters sign free newsletters new data shows monoclonal antibodies slow disease given early millions baby boomers fast approaching old age alzheimer disease diagnoses set spike hunt find medications slow halt progression common form dementia pharmaceutical companies pinned high hopes monoclonal antibodies drugs designed latch toxic protein builds brain sufferers triggers immune system break preliminary studies past decade drugs failed outperform placebos new analyzes resurrected original promise july research teams presented data alzheimer association international conference washington d.c. suggesting monoclonal antibodies potentially stall alzheimer relentless progression provided given early high doses experimental drugs target beta amyloid protein fragment heart